Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757405 | 0.90 | SLC2A1 (0.59) | CCR8HTR1ASIGMAR1KCNH2SLC2A1 | |
| SCHEMBL6985890 | 0.84 | CCR8 (0.49) | CCR8HTR1ASIGMAR1KCNH2SLC2A1 | |
| SCHEMBL5754351 | 0.80 | SIGMAR1 (0.47) | HTR1ASIGMAR1 | |
| SCHEMBL6485496 | 0.78 | SLC2A1 (0.53) | KCNH2SLC2A1 | |
| SCHEMBL6485488 | 0.78 | SLC2A1 (0.53) | KCNH2SLC2A1 | |
| SCHEMBL6485492 | 0.78 | SLC2A1 (0.53) | KCNH2SLC2A1 | |
| SCHEMBL6866210 | 0.76 | SLC2A1 (0.53) | CCR8KCNH2SLC2A1KDM4EALDH1A1 | |
| SCHEMBL6498397 | 0.76 | SLC2A1 (0.60) | CCR8KCNH2SLC2A1KDM4EALDH1A1 | |
| SCHEMBL6645387 | 0.76 | SLC2A1 (0.60) | CCR8KCNH2SLC2A1KDM4EALDH1A1 | |
| SCHEMBL6498402 | 0.76 | SLC2A1 (0.60) | CCR8KCNH2SLC2A1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343765-B1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERAZINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2006-11-22 | — | — | EP | claimed |
| US-20040077656-A1 | Quinolines and nitrogenated derivatives thereof substituted in 4-position by a piperazine-containing moiety and their use as antibacterial agents | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-22 | — | — | US | claimed |
| EP-1343765-A1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERAZINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-09-17 | — | — | EP | claimed |
| WO-2002050040-A1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERAZINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2002-06-27 | — | — | WO | claimed |
| EP-1343765-B1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERAZINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20040077656-A1 | Quinolines and nitrogenated derivatives thereof substituted in 4-position by a piperazine-containing moiety and their use as antibacterial agents | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077656-A1 | Quinolines and nitrogenated derivatives thereof substituted in 4-position by a piperazine-containing moiety and their use as antibacterial agents | NQO2, ASNS, QARS1 | CCR8 3980/4885HTR1A 2106/4885SIGMAR1 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.